药物基因组学市场分析及预测(按规模、份额、增长、趋势)2028

  • Report Code : TIPRE00007564
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 239
Buy Now

药物基因组学市场预计将从 2021 年的 70.8781 亿美元增至 2028 年的 141.0780 亿美元;预计2021年至2028年复合年增长率为10.3%。

慢性病患病率的增加是推动市场增长的最关键因素之一。许多老年人(>60%)患有两种或多种慢性病。双胞胎研究表明,基因可能导致慢性疾病,如心血管疾病 (CVD)、糖尿病、肥胖、类风湿性关节炎、阿尔茨海默病 (AD) 和抑郁症。利用全基因组关联研究 (GWAS) 的分子遗传数据,现在可以测量这些慢性疾病的个体风险。根据美国疾病控制与预防中心 (CDC) 的数据,2020 年,美国近十分之六的人患有至少一种慢性病,十分之四的人患有两种或两种以上慢性病。慢性病正在引发对药物基因组学技术开发新疗法的需求。

 


北美可能主导药物基因组学2021-2028 年市场。美国占据北美市场最大份额,预计在预测期内将继续这一趋势。由于开发治疗癌症的精准医学的研究活动不断增加,领先的生物制药和制药公司的存在不断增加,以及美国药物基因组学研究的不断发展,美国药物基因组学市场预计在未来几年将增长。基于药物基因组学的癌症治疗的采用率不断上升,领先的市场参与者正在推出几种与这种方法相关的新产品。此外,监管机构的支持预计将在预测期内推动美国市场。目前,多项临床试验正在研究药物基因组学技术,以开发精准药物并提高治疗的总体反应率。 2021年5月,美国食品药品监督管理局(FDA)批准Lumakras(Sotorasib)用于靶向治疗KRAS基因表达G12C突变肿瘤的非小细胞肺癌患者。

 

药物基因组学市场利润丰厚的区域


 

市场洞察

药物基因组学资金不断增加研究推动市场增长

基因组测序越来越多地应用于临床实践,未来五年,预计医疗保健系统将生成来自超过 6000 万患者的基因组数据。药物基因组学正在迅速过渡到临床实践,并在至少 14 个国家的政府投资支持下,在医疗保健系统中的实施总额超过 40 亿美元。

英国已宣布全球最大的基因组项目是慈善机构和制药公司之间 2 亿欧元公私合作的一部分。作为英国研究与创新的一部分,英国已经通过创新英国领导的 100,000 个基因组项目开发了世界上最大的基因组数据库。该项目将资助研究人员和行业将英国医疗保健服务的数据和现实证据相结合,创造出能够有效诊断疾病的新产品和服务。

此外,2018 年 8 月总部位于马萨诸塞州的波士顿科学公司 (Boston Scientific Corporation) 宣布获得 430 万美元种子资金,并与 Veritas Genetics 合作。这些资金将支持公司的使命,即通过创建一个值得信赖、安全和去中心化的基因组数据市场来进入个人基因组测序时代。

 

基于技术见解

根据技术,药物基因组学市场分为 PCR、测序、微阵列、凝胶电泳、质谱等。 PCR 市场进一步细分为标准 PCR、实时 PCR 和数字 PCR。预计 PCR 领域将在 2021 年至 2028 年占据药物基因组学市场的最大份额。聚合酶链式反应 (PCR) 是一种常用技术,可快速产生数百万至数十亿份特定 DNA 样本,使科学家能够获取少量 DNA 样本并将其扩增至足够数量以进行详细研究。 PCR技术在基因克隆与操作、DNA克隆、基因突变、基因功能分析、病原体检测、耐药性测定等方面发挥着关键作用。各种制药和生物制药公司为药物基因组学和药物开发应用提供 PCR 解决方案。例如,Thermo Fisher Scientific, Inc 为药物基因组学应用提供实时 PCR 解决方案。

 

药物基因组学市场,按技术划分 – 2021 年和 2028 年


 

申请 –基于洞察

根据应用,药物基因组学市场分为药物发现、肿瘤学、神经病学和精神病学、疼痛管理、心血管疾病等。肿瘤学领域拥有相当大的市场份额,预计在预测期内将继续占据主导地位。癌症药物基因组学为当前的癌症治疗做出了多项重要发现,改变了治疗决策的范式。世界卫生组织(WHO)表示,2020年癌症将导致约1000万人死亡。此外,根据美国癌症协会的数据,预计全球癌症负担每年将增至2750万新发病例和1630万癌症死亡病例2040年。如此高的数字表明癌症发病率的上升对原始诊断和预防性治疗提出了要求。有多种方法可以诊断癌症,例如 PCR、INAAT 和 NGS。 PCR(聚合酶链式反应)的概念带来了临床 DNA 检测的巨大进步。基于 PCR 的方法需要简单的仪器和基础设施,仅利用微量的生物材料,并且与临床常规广泛协调。由于化疗药物的治疗指数逐渐递减以及危及生命的不良反应的风险,药物基因组学在肿瘤学中的应用具有重要意义。

     

最终用户——基于洞察

根据最终用户,药物基因组学市场分为医院和诊所、生物制药公司、CRO 和 CDMO 等。 CRO 和 CDMO 领域拥有相当大的市场份额,预计在预测期内将继续占据主导地位。合同研究组织(CRO)帮助各种公司和组织对其开发的产品和技术进行临床试验,而合同开发和制造组织(CDMO)则协助公司开发和制造产品。 CRO 提供的服务包括项目管理、数据库设计和构建、数据录入和验证、临床试验数据管理、医学和疾病编码、质量和指标报告、统计分析计划和报告、验证编程以及安全性和有效性总结和最终研究报告。 CRO 还 提供一些其他服务,例如基因服务、克隆服务和表达。

 

在药物基因组学市场运营的公司采用无机增长战略,以满足世界各地不断变化的客户需求,其中包括收购、合并以及与全球市场上的本地和国际参与者的合作。

 

药物基因组学市场–细分

  • 根据技术,药物基因组学市场分为PCR、测序、微阵列、凝胶电泳、质谱等。 PCR 领域的市场进一步细分为标准 PCR、实时 PCR 和数字 PCR。
  • 按照应用,药物基因组学市场细分为药物发现、肿瘤学、神经病学和精神病学、疼痛管理、心血管
  • 根据最终用户,药物基因组学市场分为医院和诊所、生物制药公司、CRO 和 CDMO 等。
  • 按地理位置划分,皮内注射市场细分为北美(美国、加拿大和墨西哥)、欧洲(法国、德国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国、印度、日本、韩国)和亚太地区其他地区)、中东和非洲(沙特阿拉伯、南非、阿联酋和 MEA 的其他地区)以及南美洲和中美洲(巴西、阿根廷和 SCAM 的其他地区)。

F.霍夫曼拉罗氏有限公司;雅培;牛津纳米孔技术;赛默飞世尔科技公司;照明公司;凯杰;安捷伦科技公司;无数遗传学公司;阿德梅拉健康;和 Dynamic DNA Laboratories 是在药物基因组市场运营的几家公司。

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which is the most influencing segment growing in the pharmacogenomics market report?

The global pharmacogenomics market based on technology is segmented into sequencing, PCR, gel electrophoresis, mass spectrometry, microarray, and others. In 2021, the PCR segment held the largest share of the market by technology and it is expected to witness fastest CAGR during 2021 to 2028, due to increasing utilization of this technology at global level.

What is the market value of pharmacogenomics market based on region?

The global pharmacogenomics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North American area holds the largest market for pharmacogenomics. The United States held the most significant pharmacogenomics market and is expected to grow due to factors such as the increasing prevalence of chronic diseases and growing investments while the technological advancements by key players in pharmacogenomics is also boosting the growth rate in US.
The Asia Pacific region is expected to account for the fastest growth in the pharmacogenomics market. In Japan, India and South Korea, the market is expected to grow owing to the rapid development of research organizations and biopharmaceutical companies.

What are the factors impacting for the Pharmacogenomics market?

Several factors are believed to affect pharmacogenomics market in the coming years. Factors such as growing adoption of personalized therapies, increasing prevalence of chronic diseases, and growing funding in this sector are driving the market growth. However, lack of skilled professionals is likely to hamper the growth of the market.

Who are the major players in the pharmacogenomics market?

The pharmacogenomics market majorly consists of the players such as F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc.; Illumina, Inc.; QIAGEN; Agilent Technologies, Inc.; Myriad Genetics, Inc.; Admera Health; Dynamic DNA Laboratories among others..

What is Pharmacogenomics?

Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies. Pharmacogenomics has direct application in the development of personalized medicine by testing single or multiple genes that are related to the disease. The main aim of this technology is to reduce the occurrence of treatment related adverse events and reduction in overall cost of treatment. The growing cases of ADRs and increasing demand of personalized therapies are expected to trigger the growth rate of this segment.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Pharmacogenomics Market

  1. F. Hoffmann-la Roche Ltd
  2. Abbott
  3. Oxford Nanopore Technologies
  4. Thermo Fisher Scientific Inc.
  5. Illumina, Inc.
  6. QIAGEN
  7. Agilent Technologies, Inc.
  8. Myriad Genetics, Inc.
  9. Admera Health
  10. Dynamic DNA Laboratories

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.